Phase II study of the effectiveness of prophylaxis against side effects associated with Afatinib (NLCTG 1401)
Phase 2
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000016167
- Lead Sponsor
- iigata Lung Cancer Treatment Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
(1)History of active double cancer (2)No intention to birth control (3)Unstable psychic disorder (4)Interstitial pneumonia or active radiation pneumonia or drug-induced pneumonia (5)Ileus (6)Patients who can not take oral drugs (7)Severe complications (8)Patients in drug and tetracycline drug used in the present study a history of hypersensitivity (9)Decision of ineligibility by a physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method